| Steven
D. Nathan, MD
Medical Director, Lung Transplant Program
Medical Director, Advanced Lung Disease Program
Inova Fairfax Hospital
Falls Church, Virginia
Steven D. Nathan, MD, is the Director of the Advanced Lung Disease
Program and the Medical Director of the Lung Transplant Program
at Inova Fairfax Hospital in Falls Church, Virginia. He is also
an Affiliate Professor of Biomedical Sciences at George Mason University.
Dr. Nathan received his medical degree at the University of the
Witwatersrand Medical School in Johannesburg, South Africa. He completed
his internship in Internal Medicine and General Surgery at the Johannesburg
Hospital. Dr. Nathan performed his Internal Medicine residency at
Long Island Jewish Hospital in New York City, and completed his
fellowships in Pulmonary Medicine, Critical Care, and Lung Transplantation
at Cedars-Sinai Medical Center in Los Angeles, California. He is
board certified in Internal Medicine, Pulmonary Diseases, and Critical
Care Medicine.
Dr. Nathan has been widely published in a number of peer-reviewed
journals and publications, such as Chest and the Journal
of Heart and Transplantation. He has since been awarded the
Jubilee Award for his achievements from the University of the Witwatersrand.
He also sits on the editorial board for Progress in Transplantation.
Dr. Nathan is a member of several professional medical associations,
including the American Thoracic Society and the International Society
for Heart and Lung Transplantation, and is a member of the American
College of Chest Physicians Network Interstitial Lung Disease Steering
Committee.
Disclosure Statement
The France Foundation relies upon faculty members to provide educational
information in a manner that is objective and free from bias. In
compliance with the Accreditation Council for Continuing Medical
Education's (ACCME) Standards for Commercial Support, all faculty
members are required to disclose any conflicts of interest related
to the context of their participation in a CME activity. Faculty
members have disclosed the following relationships with commercial
interests:
Steven D. Nathan, MD, has served as a consultant for Actelion, Gilead, InterMune, and United Therapeutics. He has received research support from Actelion, InterMune, and United Therapeutics and honoraria from Actelion, Gilead, and Pfizer.
Disclaimer The opinions, recommendations, and guidelines
expressed herein are those of the PILOT Steering Committee and
other contributing faculty, and not necessarily those of The France
Foundation or InterMune, who assume no responsibility or liability
for the material that appears herein. |